Diffuse tenosynovial giant cell tumor
Updates to Article Attributes
Diffuse tenosynovial giant cell tumour is an uncommon benign condition, which is most commonly monoarticular (~70% knee joint) but occasionally it can be polyarticular.
Please see the overview article tenosynovial giant cell tumour for content common to both the localised-type and diffuse-type.
Epidemiology
Diffuse tenosynovial giant tumours occur predominantly in early middle age (<40 years) 1,2,11. In intra-articular disease, there is no gender predilection, whereas extra-articular disease has a slight female predominance ref.
Clinical presentation
Presentation is usually with joint swelling, pain and reduced range of motion 11. Haemarthrosis is common 11. Usually, symptoms have been present for many months or years before the diagnosis is made.
Although unusual in the paediatric population, it is sometimes seen and is more frequently poly-articular. It has also been described in association with 2:
extremity lymphoedema
vascular lesions
Pathology
Typically diffuse tenosynovial giant cell tumours are a monoarticular and joints with large synovial surfaces are predictably most frequently affected with the knee being the most frequently affected (~75%) followed by the hip (~10%), ankle, shoulder, elbow, facet joints, and rarely other joints (e.g. temporomandibular joint) 2,6,11.
Macroscopic appearance
Macroscopically, diffuse tenosynovial giant cell tumours are large (>5 cm) and are firm and sponge-like. When intra-articular, a villous pattern is usually present, and when extra-articular there are multiple nodular projections. Their colour is typically dark brown and heterogeneous with areas of yellow discolouration (xanthoma cells) 11.
Microscopic appearance
See main tenosynovial giant cell tumour article.
Radiographic features
Plain radiograph
On radiographs, features are relatively nonspecific with appearances mainly being those of a joint effusion. Bone density and joint space are preserved until the late stages. No calcification is seen. Extrinsic marginal pressure erosions may be present. There may be suggestion of focal areas of soft tissue swelling surrounding the joint +/- dense soft-tissues from haemosiderin deposition.
CT
Joint effusions commonly co-exist. The hypertrophic synovium appears as a soft tissue mass, which on account of haemosiderin, may appear slightly hyperdense compared to adjacent muscle. Calcification is very rare in the synovial mass (cf. synovial sarcoma where it is common). Erosions are often well seen on CT.
MRI
MRI typically shows mass-like synovial proliferation with lobulated or ill-defined margins. This may be extensive in the diffuse form 9 with low signal intensity due to haemosiderin deposition.
Signal characteristics
T1: low to intermediate signal
-
T2
low to an intermediate signal
some areas of a high signal may be present likely due to joint fluid or inflamed synovium
STIR: predominantly high signal 2
GE: low and may demonstrate blooming
T1 C+ (Gd): variable enhancement
Treatment and prognosis
Treatment is with complete synovectomy, which offers a good prospect of cure, provided all the synovium is excised ref. This can be difficult and therefore adjuvant treatment is often employed, especially external beam radiotherapy which offers excellent control. Intra-articular injection of yttrium-90 is an alternative ref12. Recurrence rates are reported to be ~35% (range 7-60%) 2,11.
Differential diagnosis
See main tenosynovial giant cell tumour article.
See also
-</ul><h4>Treatment and prognosis</h4><p>Treatment is with complete synovectomy, which offers a good prospect of cure, provided all the synovium is excised <sup>ref</sup>. This can be difficult and therefore adjuvant treatment is often employed, especially external beam radiotherapy which offers excellent control. Intra-articular injection of yttrium-90 is an alternative <sup>ref</sup>. Recurrence rates are reported to be ~35% (range 7-60%) <sup>2,11</sup>.</p><h4>Differential diagnosis</h4><p>See main <a href="/articles/tenosynovial-giant-cell-tumour-2" title="Tenosynovial giant cell tumour">tenosynovial giant cell tumour</a> article.</p><h4>See also</h4><ul><li><p><a href="/articles/erosive-arthritis-differential">differential diagnosis of erosive arthritis</a></p></li></ul>- +</ul><h4>Treatment and prognosis</h4><p>Treatment is with complete synovectomy, which offers a good prospect of cure, provided all the synovium is excised <sup>ref</sup>. This can be difficult and therefore adjuvant treatment is often employed, especially external beam radiotherapy which offers excellent control. Intra-articular injection of yttrium-90 is an alternative <sup>12</sup>. Recurrence rates are reported to be ~35% (range 7-60%) <sup>2,11</sup>.</p><h4>Differential diagnosis</h4><p>See main <a href="/articles/tenosynovial-giant-cell-tumour-2" title="Tenosynovial giant cell tumour">tenosynovial giant cell tumour</a> article.</p><h4>See also</h4><ul><li><p><a href="/articles/erosive-arthritis-differential">differential diagnosis of erosive arthritis</a></p></li></ul>
References changed:
- 12. Ozturk H, Bulut O, Oztemur Z, Bulut S. Pigmented Villonodular Synovitis Managed by Yttrium 90 After Debulking Surgery. Saudi Med J. 2008;29(8):1197-200. - <a href="https://www.ncbi.nlm.nih.gov/pubmed/18690320">Pubmed</a>
Unable to process the form. Check for errors and try again.